InSite licenses ophthalmic azithromycin to Nitten
This article was originally published in Scrip
Executive Summary
InSite Vision has awarded the private Japanese firm Nitten Pharmaceutical exclusive rights in Japan and Taiwan to AzaSite, an ophthalmic preparation of azithromycin.